Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells
Authors
Keywords
AML, Immunotherapy, TEGs, Mice model, Preclinical, Toxicity, TCR engineering
Journal
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-03-14
DOI
10.1186/s40425-019-0558-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib
- (2018) Hardikkumar Jetani et al. LEUKEMIA
- Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies
- (2018) Christian Chabannon et al. Science Translational Medicine
- Butyrophilin3A proteins and Vγ9Vδ2 T cell activation
- (2018) Siyi Gu et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR
- (2018) Trudy Straetemans et al. Frontiers in Immunology
- Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model
- (2018) Maaike V. J. Braham et al. OncoImmunology
- Current status and perspectives of patient-derived xenograft models in cancer research
- (2017) Yunxin Lai et al. Journal of Hematology & Oncology
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
- (2017) James L. Gulley et al. JNCI-Journal of the National Cancer Institute
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on Vγ9Vδ2 T cell activation
- (2017) Siyi Gu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types
- (2017) Caroline Lonez et al. BMJ Open
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
- (2017) James L. Gulley et al. JNCI-Journal of the National Cancer Institute
- Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscape
- (2016) Cameron J. Turtle et al. Expert Review of Hematology
- RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor
- (2016) Zsolt Sebestyen et al. Cell Reports
- High-content molecular profiling of T-cell therapy in oncology
- (2016) Ruslan Novosiadly et al. Molecular Therapy-Oncolytics
- Modeling Human Leukemia Immunotherapy in Humanized Mice
- (2016) Jinxing Xia et al. EBioMedicine
- Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer
- (2015) T. Straetemans et al. CLINICAL CANCER RESEARCH
- Engineering CAR-T cells: Design concepts
- (2015) Shivani Srivastava et al. TRENDS IN IMMUNOLOGY
- Cancer Immunotherapy Using γδT Cells: Dealing with Diversity
- (2014) Wouter Scheper et al. Frontiers in Immunology
- Clinical Applications of Gamma Delta T Cells with Multivalent Immunity
- (2014) Drew C. Deniger et al. Frontiers in Immunology
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
- (2013) G. P. Linette et al. BLOOD
- Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models
- (2013) D. Siolas et al. CANCER RESEARCH
- Hunting for clinical translation with innate-like immune cells and their receptors
- (2013) W Scheper et al. LEUKEMIA
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells
- (2013) Stefano Vavassori et al. NATURE IMMUNOLOGY
- 9 and 2CDR3 domains regulate functional avidity of T cells harboring 9 2TCRs
- (2012) C. Grunder et al. BLOOD
- Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human T-cell subset
- (2012) C. Harly et al. BLOOD
- The Molecular Basis for Modulation of Human Vγ9Vδ2 T Cell Responses by CD277/Butyrophilin-3 (BTN3A)-specific Antibodies
- (2012) Aparna Palakodeti et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Redirecting T cells against cancer cells by transfer of a broadly tumor-reactive T-cell receptor
- (2011) V. Marcu-Malina et al. BLOOD
- Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies
- (2010) M. M. van Loenen et al. HAEMATOLOGICA
- AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3
- (2010) M Wunderlich et al. LEUKEMIA
- Increasing functional avidity of TCR-redirected T cells by removing definedN-glycosylation sites in the TCR constant domain
- (2009) Jürgen Kuball et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A robust xenotransplantation model for acute myeloid leukemia
- (2009) P V Sanchez et al. LEUKEMIA
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
- (2008) Mark E. Dudley et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now